Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HAB3
UPID:
S52A2_HUMAN
Alternative names:
Porcine endogenous retrovirus A receptor 1; Protein GPR172A; Riboflavin transporter 3
Alternative UPACC:
Q9HAB3; A8K6B6; D3DWL8; G1UCY1; Q86UT1
Background:
Solute carrier family 52, riboflavin transporter, member 2 (SLC52A2), also known as Riboflavin transporter 3, plays a crucial role in the cellular uptake of vitamin B2/riboflavin. This protein is essential for the metabolism of carbohydrates, lipids, and amino acids, highlighting its importance in human nutrition and cellular function.
Therapeutic significance:
SLC52A2's dysfunction is linked to Brown-Vialetto-Van Laere syndrome 2, a neurologic disorder benefiting from riboflavin supplementation. Understanding SLC52A2's role could lead to novel therapeutic strategies for related metabolic disorders.